Advertisement
BIO vs ILMN
Which Stock Would AI Choose? Bio-Rad Laboratories (BIO) vs. Illumina (ILMN) Stock Comparison
Key Takeaways
- ILMN beat Q1 2026 earnings and revenue estimates with $1.09 billion in sales, driving a sharp intraday gain, while BIO missed forecasts.
- BIO shows stronger year-to-date gains at 16.34%, outperforming ILMN's 2.49% amid broader biotech volatility.
- ILMN boasts a larger market cap of $20.4 billion versus BIO's $6.8 billion, reflecting scale in genomics.
- Recent momentum favors ILMN after raising its full-year outlook, contrasting BIO's post-earnings drop.
- Technical analysis scores indicate mild bullish signals for both, with ILMN slightly ahead.
Introduction
Bio-Rad Laboratories (BIO) and Illumina (ILMN) stand as key players in the life sciences sector, providing essential tools for research, diagnostics, and genomics. This stock comparison analyzes their recent performance, business drivers, and market positioning amid evolving biotech demand. Traders seeking short-term momentum and investors focused on long-term healthcare innovation will find value in understanding their relative strengths, especially following fresh quarterly earnings that highlight divergent paths in a competitive landscape.
BIO Overview and Recent Performance
Bio-Rad Laboratories (BIO) develops instruments, software, and consumables for life science research and clinical diagnostics markets, including droplet digital PCR (ddPCR, a precise nucleic acid quantification technology) platforms. In recent market activity, shares traded around $253, down sharply after Q1 2026 results showed $592.1 million in revenue and normalized EPS of $1.89, missing analyst expectations of $1.99. Sentiment has been influenced by softer biotech spending and process chromatography challenges, though year-to-date gains of 16% reflect resilience. Analyst targets average $302, with recent holds amid price target cuts.
ILMN Overview and Recent Performance
Illumina (ILMN) dominates next-generation sequencing (NGS, high-throughput DNA analysis technology) with platforms like NovaSeq, serving genomics research, clinical testing, and multiomics applications. Recent weeks saw shares rise to about $134, up over 5% intraday on Q1 2026 earnings of $1.09 billion in revenue (up 4.8% year-over-year) and EPS of $1.15, topping estimates, alongside raised 2026 guidance. Positive drivers include margin expansion to 19.2% and analyst upgrades, boosting sentiment despite modest YTD returns of 2.5%. Average price targets stand at $137.
Trending AI Robots
Tickeron's Trending AI Robots page curates 25 top-performing AI trading bots from over 351 available, each employing machine learning for real-time signals across stocks, ETFs, and sectors like semiconductors and space. These bots showcase impressive stats, including annualized returns up to +164%, win rates as high as 88%, and profit factors reaching 7.0, with strategies spanning short-term (15-minute) scalping to swing trades using take-profit/stop-loss corridors. None currently feature BIO or ILMN, but their adaptability to market conditions highlights AI's edge in volatile biotech plays. Explore these bots to align with current trends.
Head-to-Head Comparison
BIO offers a diversified model blending life science reagents and diagnostics, contrasting ILMN's sequencing-focused dominance vulnerable to competition from emerging NGS rivals. Growth drivers for ILMN include whole genome sequencing adoption and multiomics, outpacing BIO's ddPCR expansions amid biotech funding headwinds. Recent momentum tilts to ILMN with its earnings beat versus BIO's miss. Risks include regulatory hurdles for ILMN post-Grail divestiture and acquisition integration for BIO. Sector exposure favors both in healthcare, but ILMN enjoys stronger sentiment via raised targets.
Tickeron AI Verdict
Tickeron's AI would currently favor ILMN over BIO, given superior recent earnings execution, upward guidance revisions, and positive price momentum in a sector favoring growth catalysts. While BIO offers value at a lower P/E, ILMN's stability and technical edge suggest higher probability of near-term outperformance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIO is a Hold and ILMN is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIO’s FA Score shows that 1 FA rating(s) are green whileILMN’s FA Score has 3 green FA rating(s).
- BIO’s FA Score: 1 green, 4 red.
- ILMN’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIO’s TA Score shows that 3 TA indicator(s) are bullish while ILMN’s TA Score has 2 bullish TA indicator(s).
- BIO’s TA Score: 3 bullish, 7 bearish.
- ILMN’s TA Score: 2 bullish, 6 bearish.
Price Growth
BIO (@Medical/Nursing Services) experienced а -2.82% price change this week, while ILMN (@Medical Specialties) price change was -3.30% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -0.22%. For the same industry, the average monthly price growth was -3.84%, and the average quarterly price growth was -16.30%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.45%. For the same industry, the average monthly price growth was +2.48%, and the average quarterly price growth was -3.19%.
Reported Earning Dates
BIO is expected to report earnings on Jul 30, 2026.
ILMN is expected to report earnings on Aug 12, 2026.
Industries' Descriptions
@Medical/Nursing Services (-0.22% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (+0.45% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| BIO | ILMN | BIO / ILMN | |
| Capitalization | 7.33B | 25B | 29% |
| EBITDA | 440M | 1.43B | 31% |
| Gain YTD | -7.221 | 23.041 | -31% |
| P/E Ratio | 46.77 | 29.34 | 159% |
| Revenue | 2.59B | 4.39B | 59% |
| Total Cash | 1.57B | 1.16B | 135% |
| Total Debt | 1.38B | 2.54B | 54% |
BIO | ILMN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 74 | 85 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 83 Overvalued | 75 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 90 | 30 | |
PRICE GROWTH RATING 1..100 | 52 | 11 | |
P/E GROWTH RATING 1..100 | 13 | 7 | |
SEASONALITY SCORE 1..100 | 90 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ILMN's Valuation (75) in the Biotechnology industry is in the same range as BIO (83) in the Medical Specialties industry. This means that ILMN’s stock grew similarly to BIO’s over the last 12 months.
ILMN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as BIO (100) in the Medical Specialties industry. This means that ILMN’s stock grew similarly to BIO’s over the last 12 months.
ILMN's SMR Rating (30) in the Biotechnology industry is somewhat better than the same rating for BIO (90) in the Medical Specialties industry. This means that ILMN’s stock grew somewhat faster than BIO’s over the last 12 months.
ILMN's Price Growth Rating (11) in the Biotechnology industry is somewhat better than the same rating for BIO (52) in the Medical Specialties industry. This means that ILMN’s stock grew somewhat faster than BIO’s over the last 12 months.
ILMN's P/E Growth Rating (7) in the Biotechnology industry is in the same range as BIO (13) in the Medical Specialties industry. This means that ILMN’s stock grew similarly to BIO’s over the last 12 months.
| BIO | ILMN | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 70% | 2 days ago 71% |
| Stochastic ODDS (%) | 2 days ago 70% | 2 days ago 84% |
| Momentum ODDS (%) | 2 days ago 69% | 2 days ago 78% |
| MACD ODDS (%) | 2 days ago 74% | 2 days ago 79% |
| TrendWeek ODDS (%) | 2 days ago 66% | 2 days ago 68% |
| TrendMonth ODDS (%) | 2 days ago 67% | 2 days ago 73% |
| Advances ODDS (%) | 8 days ago 66% | 13 days ago 70% |
| Declines ODDS (%) | 2 days ago 68% | 7 days ago 79% |
| BollingerBands ODDS (%) | 2 days ago 71% | 2 days ago 82% |
| Aroon ODDS (%) | 2 days ago 75% | 2 days ago 81% |
Advertisement
BIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, BIO has been closely correlated with A. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if BIO jumps, then A could also see price increases.
ILMN and
Correlation & Price change
A.I.dvisor indicates that over the last year, ILMN has been loosely correlated with BRKR. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if ILMN jumps, then BRKR could also see price increases.
| Ticker / NAME | Correlation To ILMN | 1D Price Change % | ||
|---|---|---|---|---|
| ILMN | 100% | -0.34% | ||
| BRKR - ILMN | 60% Loosely correlated | -1.14% | ||
| RVTY - ILMN | 58% Loosely correlated | -0.96% | ||
| AZTA - ILMN | 51% Loosely correlated | -4.46% | ||
| BIO - ILMN | 50% Loosely correlated | -0.47% | ||
| A - ILMN | 50% Loosely correlated | -0.45% | ||
More | ||||